Information for COVID-19 Therapeutics Providers

Texas Case Counts microscopic example of a coronavirus

This page contains information and resources for Texas COVID-19 therapeutics providers. Providers with questions can contact therapeutics@dshs.texas.gov or call Provider Support at 833‑832‑7068, option 0.

On this page:


News & Updates

Final Allocation of Bebtelovimab Exclusively for Under- and Uninsured Patients

Texas received a very small final distribution of bebtelovimab from the United States Government (USG) to be utilized exclusively for persons who are uninsured or underinsured. See the 9/09/22 DSHS communication to providers for more information.

Bebtelovimab Available for Purchase Week of 8/15/2022

Bebtelovimab will become available for purchase from the distributor AmerisourceBergen (ABC) during the week of August 15, 2022. See the 8/04/22 DSHS communication to providers for more information.

More Provider Notices (PDFs)

Weekly eDigests (PDFs)


How to Become a COVID-19 Therapeutics Provider

To enroll as a therapeutics provider, please email therapeutics@dshs.texas.gov or call Provider Support at 833‑832‑7068, option 0.


Therapeutics Products

Click on any of the buttons below to access a list of product-specific resources.

Shelf-life extension information can be found individually in each of the applicable product-specific sections, as well as in the Shelf-Life Extensions section below.

For the latest information on product distribution across the state, see the Texas COVID-19 Product Availability section.

Monoclonal Antibody (mAb) Products

Bamlanivimab + Etesevimab (Lilly) Casirivimab + Imdevimab (Regeneron) Sotrovimab (GlaxoSmithKline) Bebtelovimab (Lilly)

Long-Acting Antibody (LAAB) Product

Evusheld: tixagevimab + cilgavimab (AstraZeneca)

Oral Antiviral Products

Lagevrio (molnupiravir) (Merck) Paxlovid: nirmatrelvir + ritonavir (Pfizer)

Shelf-Life Extensions



Texas COVID-19 Product Availability


Job Aids & FAQs


Webinars


Billing & Coding Information

▲ Top

This page is being updated as new information becomes available.

Last updated November 28, 2022